| text only |
|
|||||||||||||||||||||||||||||
Professional Profile
Research Interests: -Ultraviolet-induced skin cancers -Apoptosis triggered by UV-induced DNA damage -The role of pro- and anti-apoptotic factors in tumor outgrowth and progression -A systems biology approach for the integration of biomarker information and tumor behavior Honors and Academic Achievements: -Distinguished Scientist and Outstanding Alumni Award, University of South Alabama (2005) -John McGovern Award for Graduate Teaching, University of Texas Health Science Center at Houston (1999) -Preuss Foundation Postdoctoral Fellowship (1986-1989) -Robert A. Patnode Award, University of Oklahoma Health Science Center (1986) -Cora M. Downs Award, American Society of Microbiology (1986) -Noble Foundation Predoctoral Fellowship (1982-1984) Education: -Postdoctoral Fellow, The University of Texas M.D. Anderson Cancer Center (1986-1990) -Ph.D., (Microbiology/Immunology), University of Oklahoma Health Science Center (1986) -B.S., (Medical Technology), The University of South Alabama (1980) Professional Appointments: -2007-2008 Director, Research Development and Enterprise Relations School of Medicine Planning, University of California-Riverside -2003-2006 Director, Research and Development BioLegend, San Diego, CA -2000-2003 Professor, Biomedical Sciences, The University of California-Riverside Professor, Immunology Beckman Research Institute City of Hope Cancer Center -1991-2000 Assistant and Associate Professor of Immunology, The University of Texas M.D. Anderson Cancer Center -1988-1991 Research Associate/Instructor, Department of Tumor Biology, The University of Texas M.D. Anderson Cancer Center -1986-1988 Project Investigator, The University of Texas M.D.Anderson Cancer Center Professional Memberships: -American Association for cancer Research (1986-present) -Women in Cancer Research (1990-present) Service: -Member, Life Sciences Advisory Group, Alabama Science and Technology Roadmap (2009-) -Scientific Advisory Board, University of Montana Health Sciences Institute (2001-2006) -Board of Directors, American Melanoma Foundation (2003-2005) -Brigid D. Leventhal Awards Committee, AACR, (2003) -Grant review committees: Israel Science Foundation (2005) American Cancer Society (1996-2002) Concern Foundation (2002-2003) Swiss Cancer League (2000) New Zealand Cancer Society (2000) California Department of Health Services Cancer Research Program (1998) Selected Publications: Older highly cited publications related to research focus: 1. Hill, L.L., Ouitit, A., Loughlin, S.M., Ananthaswamy, H.N., Kripke, M.L., and Owen-Schaub, L.B. Fas ligand: A sensor for DNA damage critical in skin cancer eitology. Science 285:898-900, 1999 (cited more than 150 times). 2. Chan, H., Bartos, D.P., and Owen-Schaub, L.B. Activation-dependent transcriptional regulation of the human fas promoter requires NFkB p50/p65 recruitment. Mol Cell. Biol. 19:2098-2108, 1999 (cited more than 100 times). 3. Owen-Schaub, L.B., van Golen, K.L., Hill, L.L., and Price, J.E. Fas and FasL interactions suppress melanoma metastasis. J. Exp. Med. 188:1717-1723, 1998 (Cited more than 100 times). 4. Midis, G. P., Shen, Y., and Owen-Schaub, L. B. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res. 56:3870-3874, 1996 (Cited more than 100 times). 5. Owen-Schaub, L.B., Zhang, W., Cusack, J.C., Angelo, L.S., Santee, S.M., Fujiwara, T., Roth, J.A., Deisseroth, A.B., Zhang, W.W., Kruzel, E, and Radinsky, R. Wild-type p53 and a temperature-sensitive mutant induce fas/APO-1 expression. Mol. Cell. Biol. 15:30302-3040, 1995 (Cited more than 550 times). 6. Owen-Schaub, L.B., Kruzel, E., Berry, K., Radinsky, R., and Yonehara, S. Anti-Fas on non-hematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res. 54:1580-1586, 1994 (Cited more than 250 times). Recent Publications: 1. Guzman, E.A., Langowski, J.L., DeGuzman, A., Muller, H.K., Walker, A.M., and Owen, L.B. S179D prolactin diminishes the effects of UV light on epidermal gamma delta T cells. Mol. Cell Endocrinol. 280:6-12, 2008. 2. Peter, M.E., Budd, R.C., Desbarats, J., Hedrick, S.M., Hueber, A.-O., Newell, M.K., Owen, L.B., Pope, R.M., Tschopp, J., Wajant, H., Wallach, D., Wiltrout, R.H., Zornig, M., and Lynch, D.H. The CD95 Receptor: Apoptosis Revisited. Cell 129:447-450, 2007. 3. Ma, L.J., Guzman, E.A., DeGuzman, A., Muller, H.K., Walker, A.M., and Owen, L.B. Local cytokine levels associated with delayed-type hypersensitivity responses: modulation by gender, ovariectomy, and estrogen replacement. J. Endocrinol. 193:291-297, 2007. 4. Ma, L.J., Guzman, E.A., DeGuzman, A., Walter, B., Muller, J.K., Walker, A.M., and Owen, L.B. Unexpected effects of UVB in IL-10 transgenic mice: Normalization of contact hypersensitivity response. Arch. Dermatol. Res. 297:417-420, 2006. 5. Doherty, S.D., Ni, X., Doherty, C.B., Jones, D., Zhao, X., Owen, L.B., and Duvic, M. Abnormal expression of interleukin-23 in mycosis fungoides/Sezary syndrome lesions. Arch. Dermatol. Res. 298: 353-356, 2006. 6. Maeda, Y., Hwang-Verslues, W.W., Wei, G., Fukazawa, T., Durbin, M.L., Owen, L.B., and Sladek, F.M. Tumor suppressor p53 down regulates the expression of the human hepatocyte nuclear factor 4alpha (HNF4alpha) gene. Biochem. J. 400:303-313, 2006. 7. Yang, N.Y., Pasquale, E.B., Owen, L.B., and Ethell, I.M. The EphB4 receptor tyrosine kinase promotes the migration of melanoma cells through rho-mediated actin cytoskeleton reorganization. J. Biol. Chem. 281:32574-32586, 2006. |
||||
Laurie Owen, Ph.D.University of South Alabama - Mobile Alabama 36688-0002 Appointments: Medical, Surgical and Gynecologic Oncology: (251) 665-8000 Radiation Oncology: (251) 445-9615 Administration: (251) 460-6993 For questions or comments Contact Us Date last changed: October 27, 2009 3:55 PM http://www.southalabama.edu/mci/owen.html |
 |